This Curia white paper explores how integrating early- and late-stage API process development accelerates timelines for fast-track and orphan drugs, reducing phase 1 material production to 12–16 months. Traditionally, early stages focused only on supply, leaving cost, optimization, and validation until later, slowing progress. Curia recommends addressing synthesis optimization, polymorph selection, regulatory starting materials, and automation early. Tools like process analytical technology, AI-driven reaction predictability, and strong in-house analytics cut time and cost. Effective tech transfer and thorough late-stage validation ensure scalability, compliance, and consistent quality.

Join for free to read